首页> 外文期刊>Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association >Thyroxine treatment induces upregulation of renin-angiotensin-aldosterone system due to decreasing effective plasma volume in patients with primary myxoedema.
【24h】

Thyroxine treatment induces upregulation of renin-angiotensin-aldosterone system due to decreasing effective plasma volume in patients with primary myxoedema.

机译:由于原发性粘液水肿患者的有效血浆容量减少,甲状腺素治疗可诱导肾素-血管紧张素-醛固酮系统上调。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: In experimental animals and humans, hypothyroidism is associated with fluid retention and generalized oedema, increased antidiuretic hormone (ADH), decreased atrial natriuretic hormone (ANH), and decreased renin-angiotensin-aldosterone system (RAAS), which subsequently can be corrected by thyroid hormone replacement. The purpose of this study was to determine the effect of thyroxine therapy on RAAS and neurohormones affecting water and electrolyte metabolism and the reason for these changes in patients with primary myxoedema. METHODS: We measured changes in the plasma renin activity (PRA), serum aldosterone (Aldo), ADH, ANH levels, serum and 24 h urinary electrolytes and osmolalities, and cardiac function in 22 female patients with primary myxoedema before and after correction of hypothyroidism. We also evaluated age-, sex-, and BMI-matched 15 healthy control subjects (Cont). RESULTS: It took an average of 4.3 months (range, 3-9 months) to normalize thyroid function. The mean reductions of body weight and estimated plasma volume were 1.8+/-1.0 kg (P=0.002) and 8.5% (P<0.001), respectively. In addition, serum Na+ and osmolality and the haematocrit were significantly elevated after correction of hypothyroidism (P<0.01 and P<0.001, respectively). Increased F(E)Na and C(OSM) (P<0.05) levels in patients with hypothyroidism (Ho) compared with those in Cont did not change after thyroxine therapy (Eu). However, C(H(2)O), U(E)K, F(E)K, and TTKG levels as well as creatinine clearance (Ccr) were markedly increased in Eu compared with Ho and Cont (P<0.01, respectively). Increased plasma ADH concentration and decreased plasma ANH concentration were normalized compared to Cont after thyroxine therapy (P<0.001 and P<0.01, respectively). Low PRA and serum Aldo concentration in Ho were significantly increased in Eu (P<0.001 and P<0.01, respectively). In addition, increased left ventricular mass index and decreased cardiac output in Ho were normalized compared to Cont after thyroxine therapy (P<0.01, respectively) CONCLUSIONS: These findings suggest that the exaggerated upregulation of RAAS after correction of hypothyroidism in patients with primary myxoedema is associated with an increase in Ccr and a decrease in plasma volume resulting from water diuresis, natriuresis, osmotic diuresis and inappropriate changes in plasma ADH and ANH levels. The improved renal function coincided with an amelioration of cardiac function. These changes seem to be an adaptive response for preventing excessive plasma volume and weight loss after thyroxine therapy.
机译:背景:在实验动物和人类中,甲状腺功能减退症与体液and留和全身性水肿,抗利尿激素(ADH)升高,心房钠尿激素(ANH)降低以及肾素-血管紧张素-醛固酮系统(RAAS)降低有关,随后可予以纠正通过甲状腺激素替代。这项研究的目的是确定甲状腺素治疗对影响水和电解质代谢的RAAS和神经激素的影响,以及原发性粘液水肿患者发生这些变化的原因。方法:我们测量了22例甲状腺功能减退症矫正前后女性原发性粘液水肿患者的血浆肾素活性(PRA),血清醛固酮(Aldo),ADH,ANH水平,血清和24 h尿液和渗透压,心功能的变化。 。我们还评估了年龄,性别和BMI匹配的15名健康对照受试者(续)。结果:平均花费4.3个月(3-9个月)使甲状腺功能恢复正常。体重的平均降低和估计的血浆体积分别为1.8 +/- 1.0 kg(P = 0.002)和8.5%(P <0.001)。此外,甲状腺功能减退症矫正后,血清Na +和渗透压和血细胞比容显着升高(分别为P <0.01和P <0.001)。甲状腺功能减退(Ho)的患者的F(E)Na和C(OSM)水平升高(P <0.05),与Cont相比,甲状腺素治疗(Eu)后没有变化。然而,与Ho和Cont相比,Eu中的C(H(2)O),U(E)K,F(E)K和TTKG水平以及肌酐清除率(Ccr)显着增加(分别为P <0.01) )。甲状腺素治疗后,与Cont相比,血浆ADH浓度升高和血浆ANH浓度降低被归一化(分别为P <0.001和P <0.01)。 Eu中的低PRA和Ho中的血清Aldo浓度显着增加(分别为P <0.001和P <0.01)。此外,甲状腺素治疗后,与Cont相比,左室质量指数的增加和Ho的心输出量的减少被归一化(分别为P <0.01)。结论:这些发现表明,原发性粘液水肿患者纠正甲状腺功能减退后,RAAS的过度上调是正常的。与水利尿,利尿,渗透性利尿以及血浆ADH和ANH水平的不当变化导致的Ccr升高和血浆量减少有关。肾功能改善与心脏功能改善同时发生。这些变化似乎是预防甲状腺素治疗后血浆容量过多和体重减轻的适应性反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号